5-Amino-1MQ Dosage, Reconstitution & Mixing Trends

Explore 5-amino-1mq calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.

Anonymized 5-amino-1mq calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.

What 5-Amino-1MQ Is

5-Amino-1MQ is a small-molecule NNMT inhibitor (not a peptide) most often sourced for fat-loss and metabolic research, usually taken orally. It is commonly sold as capsules or powder and stocked alongside metabolic peptides.[1]

NNMT methylates nicotinamide to 1-methylnicotinamide, consuming the methyl donor S-adenosylmethionine (SAM) and depleting the NAD+ salvage pool. Inhibiting NNMT with 5-Amino-1MQ is hypothesized to restore SAM and NAD+ pools, shift adipocyte energy balance toward expenditure, and reduce diet-induced obesity in animal models.[1]

Pre-clinical work has reported reduced adipose-tissue mass, improved glucose homeostasis, and increased energy expenditure in diet-induced-obesity mouse models.[2] No human clinical trials have been published. Research interest extends to skeletal-muscle aging and sarcopenia.[3]

Not FDA-approved for any indication. Small-molecule research compound for in vitro / non-clinical use only.

5-Amino-1MQ Research Sources

5-Amino-1MQ Dosing Context

5-Amino-1MQ has a reported half-life of ~4 hours (estimated). The pharmacokinetic reference models an interval of once daily (oral); this is not a measured community cadence or a dosing recommendation. Short-acting, so a once-daily dose clears before the next with little buildup. Taking it at the same time each day keeps the effect steady. Pharmacokinetic source: No human PK data; small-molecule NNMT inhibitor characterised only in rodent studies (Neelakantan et al. Biochem Pharmacol 2018). It is catalogued under Weight Loss on WPA.

5-Amino-1MQ Community Calculator Data

2,123 5-Amino-1MQ reconstitution calculations have been logged by the WPA community.

This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.

These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.

WPA Analysis

5-Amino-1MQ Research Background and Calculator Data

5-Amino-1-Methylquinolinium iodide (5-Amino-1MQ) is a small-molecule NNMT inhibitor developed out of the early structure-activity work on nicotinamide N-methyltransferase as a metabolic target. The mechanistic logic traces to a focused body of preclinical work on NNMT itself. NNMT is an intracellular enzyme that consumes nicotinamide as a methyl-acceptor substrate, producing 1-methylnicotinamide and depleting the nicotinamide pool that would otherwise be recycled into NAD+ via the salvage pathway. The Kraus et al. 2014 Nature paper ("Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity") established NNMT as a metabolic target by showing that genetic NNMT knockdown in mice reduced adiposity and improved insulin sensitivity on a high-fat diet, and the downstream small-molecule inhibitor work — most notably the Neelakantan et al. Biochemical Pharmacology 2018 paper ("Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice") — characterized 5-Amino-1MQ specifically as a cell-permeable NNMT inhibitor that recapitulated the genetic knockdown phenotype in obese mice. Subsequent work has extended the picture to adipocyte differentiation (the molecule appears to suppress preadipocyte-to-adipocyte conversion in cell culture) and to muscle-stem-cell biology in aging.

The critical caveat for any researcher working with 5-Amino-1MQ is that the molecule has no published human clinical trial record. Every published study is preclinical — cell culture, rodent in vivo, or biochemical-mechanistic work — and there is no FDA-approved human indication anywhere in the world. There is also no published human pharmacokinetic study, no labeled dose, and no validated administration route for human use. The compound is research-grade only, and the dose, cadence, and vial-format patterns the WPA data surfaces below are the only large-scale view of how researchers are approaching it — necessarily as a community building protocols around the published mouse work and the emerging NNMT-inhibitor mechanistic framing rather than around any human-trial template.

Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.

WPA DOSING INSIGHT

Dose and Frequency Calculator Inputs

The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.

WPA RECONSTITUTION INSIGHT

Vial Size and BAC Water Calculator Inputs

Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.

These figures come from anonymized WPA peptide calculator sessions.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.